Diamedica Therapeutics Inc Stock Price, News & Analysis

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced the appointment of David Wambeke as Chief Business Officer (CBO) to spearhead business development initiatives. Mr. Wambeke brings over 15 years of life sciences and investment banking experience, having previously been involved in over 100 financing transactions. He will play a crucial role as the company resumes enrollment in its ReMEDy2 trial for acute ischemic stroke (AIS).

In conjunction with his appointment, Mr. Wambeke purchased $750,000 worth of common shares at $1.60 each, above the closing price of $1.57 on April 10, 2023, indicating his vested interest in the company's future. Additionally, he received an inducement stock option for 140,000 common shares with a 10-year term.

DiaMedica Therapeutics (Nasdaq: DMAC) provided a business update and 2022 financial results, highlighting ongoing communications with the FDA regarding the clinical hold on its ReMEDy2 trial. The company completed Part 1 of an in-use study, with results indicating a proposed dose revision could prevent hypotension issues. As of December 31, 2022, DiaMedica reported cash and investments of $33.5 million, a decline from $45.1 million in 2021, primarily due to operational costs. R&D expenses decreased to $7.8 million, while G&A expenses rose to $6.2 million. Management will discuss these results in a conference call on March 29, 2023.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will announce its full-year 2022 financial results after market close on March 28, 2023. A live conference call to discuss the results and provide a business update is scheduled for March 29, 2023, at 7:00 AM Central Time. Interested parties can join the call by dialing (877) 550-1858 or via webcast. DM199, DiaMedica's lead candidate, is a recombinant KLK1 protein aimed at treating acute ischemic stroke. The webcast will be available for playback on the company's website for 12 months post-call.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical firm, announced that CEO Rick Pauls will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. Mr. Pauls is scheduled to speak at 2:40 p.m. ET on March 15, and will also be available for one-on-one investor meetings throughout the event. DiaMedica's lead candidate, DM199, is the first synthetic form of the KLK1 protein, aiming to treat acute ischemic stroke and chronic kidney disease. Investors can contact their Oppenheimer representative to arrange meetings.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the appointment of Tanya Lewis to its board of directors, effective March 1, 2023. With over 25 years in drug development, Ms. Lewis has a proven track record, having held leadership roles at Replimune Group and Karyopharm Therapeutics. Her experience includes overseeing the approval of several new drugs, including XPOVIO^®. The board welcomed her expertise at a pivotal time for DiaMedica as they work to address the clinical hold on their ReMEDy2 AIS trial. Ms. Lewis aims to support the company’s mission of providing treatment options for stroke patients.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) provided an update on its clinical developments and financial results for Q3 2022. The FDA has maintained a clinical hold on the ReMEDy2 trial, requesting additional data regarding IV infusion materials. The company is preparing for an in-use study and plans to request a Type A FDA meeting. As of September 30, 2022, DiaMedica reported cash and investments of $36.1 million, down from $45.1 million at year-end 2021. R&D expenses decreased to $1.6 million, while G&A expenses rose to $1.5 million, reflecting increased operational support costs.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, announced that President and CEO Rick Pauls will participate in the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022, in New York. The conference presents an opportunity for investors to schedule meetings with DiaMedica’s management through their Craig-Hallum representative. DiaMedica focuses on developing innovative treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease.